Answers are grounded in this paper and cite their sources.
INTRODUCTION: tree that can exhibit dose-dependent stimulant, analgesic, and sedative effects through mu-opioid agonism and other mechanisms. In the United States, kratom is regulated at the state and local level in some areas but is not federally regulated. As such, it is available for purchase at head shops and gas stations in many markets, as well as through the internet. There are limited data describing Neonatal Opioid Withdrawal Syndrome in children born to mothers using kratom. We seek to further describe neonatal kratom-associated withdrawal using cases reported to United States poison centers. METHODS: for all exposures of kratom in children < 21 days of age from January 1, 2015 through December 31, 2023. We reviewed de-identified notes, or poison centers completed an online data entry form to provide additional data about the exposure. RESULTS: There were 20 reported exposures; 14 were included. Median symptom duration was eight days. Symptoms included agitation, tremor, increased tone, tachypnea, decrease oral intake, and weight loss. Nine of 14 received opioid therapy (most commonly morphine and/or methadone), generally starting within 1-3 days after the consult when reported. DISCUSSION: Neonatal opioid withdrawal syndrome may occur in a child exposed to kratom in utero. Our data predate widespread availability of 7-hydroxymitragynine products and exposures were reported only as kratom, limiting the interpretation about current risks. CONCLUSION: Maternal use of kratom during pregnancy is associated with neonatal opioid withdrawal syndrome in neonates immediately or shortly following birth. Women who are pregnant or are planning to become pregnant and use kratom should be counseled on possible risks.
No takes yet. Share an insight, caveat, or question.
Leonard et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: